Sarah Cannon Transplant and Cellular Therapy Registry work led by Drs Rao and Battiwalla comparing bendamustine vs. Flu/Cy LD chemo prior to #CART in #Lymphoma. This was done during period of Flu shortage. No difference in OS, PFS, CRS, ICANS. www.astctjournal.org/article/S266...

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study - The Lancet Haematology #mmsm #bmtsm www.thelancet.com/journals/lan...

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity - Clinical Lymphoma, Myeloma and Leukemia www.clinical-lymphoma-myeloma-leukemia.com/article/S215...

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity #mmsm #bmtsm www.clinical-lymphoma-myeloma-leukemia.com/article/S215...

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm jhoonline.biomedcentral.com/articles/10....

Full article: Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable www.tandfonline.com/doi/full/10....

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine www.nejm.org/doi/full/10....

Stem Cell Transplantation & Cellular Therapy Fellowship- UT MD Anderson Cancer Center careercenter.asco.org/job/7623735/...

Dara+ Len vs. Len alone as maintenance post autoSCT in NDMM: the AURIGA study. Dara + Len was associated with a better MRD -ve conversion and 30-month PFS #bmtsm #mmsm doi.org/10.1182/bloo...

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine #mmsm #bmtsm @nejm.org www.nejm.org/doi/full/10....

Highlights of ASH 2024: Focus on Multiple Myeloma #ASH24 #mmsm #bmtsm opmed.doximity.com/articles/hig...

GMMG-HD7 trial: Isa-VRD vs. VRD in transplant-eligible NDMM, N=662, Significantly higher MRD -ve (66 vs. 48%) and longer PF (3-year PFS: 88 vs. 71%) with Isa-VRD #bmtsm #mmsm ascopubs.org/doi/10.1200/JC…

High serum BCMA level and high metabolic tumor volume measured by PET/CT predict inferior PFS in RRMM treated with anti-BCMA CAR-T. Poor correlation seen between the two tests #bmtsm #mmsm ashpublications.org/blood/articl...

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. N=1304, Gain 1q seen in 43% patients, all others in <10%. t(4;14), del 17p (>20% cells) and Gain 1q => shorter PFS and OS #bmtsm #mmsm onlinelibrary.wiley.com/doi/10.1002/...

#ASH24 First-in-human, dose escalation study of ISB 2001 (BCMAxCD38xCD3 trispecific antibody) in RRMM. N=14, CRS: 71% (gr 1 or 2), ORR: 75%. #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Cevostamab (anti-FcR5H bispecific), in RRMM. N=167, prior LOT: 6, 57% with prior anti-BCMA Rx. EMD: 28%. ORR: 43% (60% in anti-BCMA-naive). Infections: 53.9% #mmsm #bmtsm #ASH24 ash.confex.com/ash/2024/web...

#ASH24 Cilta-cel vs. SOC in RRMM (1-3 lines), CARTITUDE-4; MRD- update. N=419, median F/U: 33.6 months. >3-fold increase in MRD -ve with cilta-cel #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Phase II trial of Anito-cel in RRMM #mmsm #bmtsm N=58, ORR: 95%, CR: 62%, MRD- 10^-5: 92%, CRS: 84%, no delayed neurotoxicity #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...

The best books of 2024, as chosen by The Economist www.economist.com/culture/2024...

ASTCT recently released a special issue of Transplantation and Cellular Therapy dedicated to the latest research, challenges and innovations in chronic #GVHD management. #bmtsm www.astctjournal.org/issue/S2666-...

CULTURE: The Story of Us, From Cave Art to K-Pop, by Martin Puchner: Book Review www.nytimes.com/2023/02/07/b...

The Dawn of Everything by David Graeber and David Wengrow: Book Review @theguardian1.bsky.social www.theguardian.com/books/2021/o...

The Invention of Good and Evil: A World History of Morality. By Hanno Sauer. Book review @theeconomistevents.bsky.social www.economist.com/culture/2024...

Optimal infused CD34+ cell dose in NDMM patients undergoing upfront autoHCT: >2.5 × 106 cells/kg. Phenomenal work by #orenpasvolsky @mdanderson.bsky.social #mmsm #bmtsm www.nature.com/articles/s41...

Outcomes of upfront AutoHCT (b/w 2008-2018) in NDMM With Del 17p. N=115, median PFS: 19.9 months, median OS: 71.5 months #mmsm #bmtsm @mdanderson.bsky.social www.sciencedirect.com/science/arti...

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky

📢 Out in the European Journal of Hematology 🙌🏼 Red cell aplasia is uncommon but causes significant morbidity 😭 Daratumumab is effective, well tolerated, and leads to rapid and sustained responses 💪🏼 doi.org/10.1111/ejh....

8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier. We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed #Hemesky

An immigration fix to address the health care workforce crisis: Use graduates of U.S. schools to fill much-needed medical jobs @statnews.bsky.social www.statnews.com/2024/11/25/i...

#ASH24 Dara-Len vs. Len maintenance in NDMM, MRD+ post ASCT (AURIGA trial). N=200, higher MRD (10^-5 NGS) and PFS with Dara-Len. Higher gr 3/4 TEAE with Dara-Len #mmsm #bmtsm ash.confex.com/ash/2024/web...

Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL, with a low incidence of grade 3 or higher immune-related toxic effects #leusm #cartcell www.nejm.org/doi/full/10....

#ASH24 MajesTEC-4 Trial (safety run-in). Tec-Len and Tec alone as post autoHCT maintenance. N=94. 3 mg/kg q 4wk associated with lower gr 3-4 infections (28-41% vs. 66%) than q 2 wk. 100% MRD-ve CR in cohort 1: N=32 (12-month f/u) #mmsm #bmtsm ash.confex.com/ash/2024/web...

Tech and religion are very much alike www.economist.com/culture/2024... from The Economist

Scientific publishers are producing more papers than ever www.economist.com/science-and-... from The Economist

#ASH24 Circulating Tumor Cells (CTC) as a biomarker for TE NDMM in Perseus trial (D-VRd vs. VRd) -CTC is an independent prognostic factor -HR cytogenetics + CTC => dismal outcome #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 GMMG-HD7 Trial (Isa-VRd vs. VRd induction) -More pts achieved MRDneg and continued MRDneg with Isa-VRd -Pts with MRDneg and continued MRDneg had longer PFS regardless of the induction arm #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Peripheral Residual Disease (PRD) by mass spect and MRD by NGF in NDMM (GEM2017FIT Trial) -79.6% concordance -integration of PRD into routine clinical practice may be beneficial for all elderly pts #mmsm ash.confex.com/ash/2024/web...